How much funding has Symbiomix raised?

Symbiomix has raised $41.0M in total funding, most recently a Series A round.

Who are Symbiomix's investors?

Symbiomix's investors include OrbiMed, Lupin, HBM Healthcare Investments, F-Prime Capital.

Where is Symbiomix headquartered?

Symbiomix is headquartered in Newark, United States.

What industry is Symbiomix in?

Symbiomix operates in Biotech, Healthcare.

Symbiomix

Acquired

Newark, United States · Founded 2012 · $41.0M raised

Biotech

Healthcare

Headquarters: Newark
Founded: 2012
Business Model: B2B
Website: symbiomix.com

Total Funding: $41.0M
Last Round: $41.0M Series AMay 2015
Rounds: 2

About

Symbiomix Therapeutics was a Newark, New Jersey-based late-stage biopharmaceutical company founded in 2012 that developed medicines for neglected women's health infections. Its lead candidate, SYM-1219 (secnidazole), won FDA approval in 2017 as Solosec, the first single-dose oral treatment for bacterial vaginosis in adult women. Backed by OrbiMed, Fidelity Biosciences, and HBM Partners, Symbiomix closed a $41 million financing round before being acquired by India's Lupin Limited for $150 million in October 2017.

Summary

Symbiomix is a Biotech company based in Newark, United States, founded in 2012. It has raised $41.0M in total across 2 rounds, most recently a $41.0M Series A round in May 2015. Investors include OrbiMed, Lupin and HBM Healthcare Investments.